On May 29, 2025, Adaptimmune Therapeutics PLC held its annual general meeting, where resolutions were approved, including the re-election of directors and approval of compensation packages. 51.50% of shares were present for voting, with significant support for all resolutions, including the adoption of 2024's accounts without a dividend recommendation.